Lupin plunges nearly 4 per cent despite getting USFDA nod for bacterial infection tablets

The global pharmaceutical company, Lupin Limited announced that it has received approval for its Sulfamethoxazole & Trimethoprim oral suspension USP, 200 mg/40 mg per 5 ml from United States Food & Drug Administration (USFDA). 

The approval has been granted to commercialise the generic equivalent of Bactrim oral suspension, 200 mg/40 mg per 5 ml of Sun Pharmaceutical Industries, Inc. 

The above-mentioned drug is indicated for the treatment and prevention of a wide variety of bacterial infections (such as middle ear, urine, respiratory & intestinal infections) and a certain type of pneumonia (pneumocystis-type). 

According to MAT September 2020 data from IMS Health, Sulfamethoxazole & Trimethoprim oral suspension USP (RLD: Bactrim) had estimated annual sales of approximately US$ 19 million in the US. 

On Wednesday, the stock of Lupin Limited closed at Rs 1,000.60 per share, down by 3.80 per cent or Rs 39.55 per share on BSE. Its 52-week high is Rs 1,121.85 while the 52-week low was Rs 505 on BSE.